Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2

<p>Relationship between plasma SDX-7320 Cmax or AUC and change in platelets</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Monica M. Mita (21585118) (author)
Altres autors:	Alain C. Mita (21585121) (author), Bradley J. Carver (18491067) (author), James M. Shanahan (18491064) (author), Benjamin A. Mayes (18491052) (author), Pierre J. Dufour (18491061) (author), David Browning (21585124) (author), Alfred Anderson-Villaluz (21585127) (author), John S. Petersen (18491055) (author), David J. Turnquist (18491058) (author), Peter Cornelius (18491049) (author)
Publicat:	2025
Matèries:	Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Clinical Research and Trials Biomarkers Protein biomarkers Pharmacology Pharmacokinetics and pharmacodynamics Phase I Clinical Trials
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars